D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review
Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.
Pharma & Biotech
Pharma & Biotech
Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation
Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.
Pharma & Biotech
OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease
Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.
Pharma & Biotech
insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Pharma & Biotech
Can L’Oréal-backed funding help OliX Pharmaceuticals turn siRNA science into a broader biotech platform?
Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.
Pharma & Biotech
Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.
Pharma & Biotech
What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment
Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.
Pharma & Biotech
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.